secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001437749-26-015762
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech secures Hong Kong patent for liposomal Annamycin through 2040
-------------------------------------------------------------------------------

- Hong Kong patent No. 40073244 covers proprietary reconstitution method of liposomal Annamycin, expiring June 25, 2040.
- Invention jointly owned with The University of Texas System; extends IP protection across four continents.
- Company expects first Phase 3 clinical data release for Annamycin later this quarter.
- Existing granted/allowed patents include US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, Taiwan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926015762/0001437749-26-015762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926015762/mbrx20260507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer